- GSK
- 20 December 2024 07:29:27
Source: Sharecast
Headline results from the FIRST-ENGOT-OV44 phase III trial evaluating a combination of Zejula (niraparib) and Jemperli (dostarlimab) showed statistically significant difference compared with standard-of-care chemotherapy.
Standard-of-care platinum-based chemotherapy have high response rates, but around 85% of patients will experience disease recurrence, GSK said. Once the disease recurs, it is rarely curable.
"As part of our focus in gynaecological cancers, we continue to evaluate the potential of this combination and look forward to sharing full results from the trial," said Hesham Abdullah, senior vice president, global head oncology, at GSK's R&D division.
However, the secondary endpoint did not meet statistical significance. GSK said that further analyses are ongoing and data will be shared with health authorities.